Treatment Intensification With Temozolomide in Adults With a Glioblastoma

Inclusion Criteria: * Patient ≥18 years old * Histological diagnosis of de novo GBM (extemporaneous diagnosis or standard pathological examination). In case of extemporaneous diagnosis, the patient can be included. If the diagnosis is not confirmed, the patient will be withdrawn from study. * Time between initial surgery/biopsy and planned start of treatment (if allocated to the experimental arm) ≤ 15 days (ideally in the first 7 days) * Karnofsky performance status (KPS) ≥ 60%, or KPS \<60% only related to glioma-related motor paresis. * Adequate biological functions * Common toxicity criteria (CTC) non hematological adverse events ≤ Grade 1 (except for alopecia, nausea, vomiting and neurological symptoms) * Females of child bearing potential must have a negative serum or urine pregnancy test within 7 days prior to initiation of treatment. Sexually active patients must agree to use adequate and appropriate contraception while on study drug and for 6 months after stopping the study drug. * Standard radiation therapy deemed feasible (60 Gy, 30 fractions) * Time interval of less than 43 days between initial surgery/biopsy and planned start of radiation therapy * Written informed consent Exclusion Criteria: * Secondary or recurrent glioblastoma (GBM) * Planned use of tumor-treating electric fields * Planned use of Carmustine implants * Prior malignancy in the last 5 years before inclusion or concomitant * Severe myelosuppression * Known hypersensitivity to any of the study dr…